Uli Stilz joins Flagship while Revolution Medicines adds Alex Hoffman as commercial lead

On June 5, 2026, biotech veteran Uli Stilz announced his new position at Flagship, marking a notable personnel shift in the industry.

Stilz has spent much of the year traveling internationally, including a recent trip to Japan, where he discussed the evolving landscape of biotechnology.

At the same time, Revolution Medicines introduced Alex Hoffman as its new commercial executive, signaling a focus on expanding its market presence.

These appointments underscore the ongoing movement of experienced leaders across biotech firms as companies position themselves for future growth.